PP_1170x120_10-25-21

Moderna

FDA’s panel backs Moderna’s booster shot for high-risk groups

FDA’s panel backs Moderna’s booster shot for high-risk groups

WASHINGTON — U.S. health advisers announced Thursday that some Americans who received Moderna’s COVID-19 vaccine should get a half-dose booster to bolster protection against the virus. The panel of advisers to the Food and Drug Administration voted unanimously to recommend a booster shot for seniors, adults with other health problems, jobs or living situations that

Moderna and IBM plan to collaborate on COVID-19 vaccine supply chain

Moderna and IBM plan to collaborate on COVID-19 vaccine supply chain

ARMONK, N.Y. — Moderna  and IBM  announced their intentions to explore technologies, including artificial intelligence, blockchain and hybrid cloud, that could help support smarter COVID-19 vaccine management. Central to the effort will be a pilot of open, standardized, technology-enabled vaccine distribution approaches aimed to improve supply chain visibility and foster near real-time tracking of vaccine

Moderna begins study of COVID-19 vaccine in adolescents

Moderna begins study of COVID-19 vaccine in adolescents

CAMBRIDGE, Mass. — Moderna announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, the company’s vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of

Moderna to seek FDA approval for coronavirus vaccine

Moderna to seek FDA approval for coronavirus vaccine

WASHINGTON —  Moderna announced it would file Monday for regulatory clearance — a critical milestone that brings the United States a step closer to having two coronavirus vaccines before the end of the year. Moderna’s vaccine was 94% effective at preventing illness in a 30,000-person clinical trial, the company said — a performance that exceeds

Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint

Moderna’s COVID-19 vaccine candidate meets its primary efficacy endpoint

CAMBRIDGE, Mass. — Moderna announced on Monday that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known

Moderna COVID-19 vaccine could be ready by December

Moderna COVID-19 vaccine could be ready by December

NEW YORK —  According to published reports, the U.S. could authorize emergency use of Moderna’s experimental COVID-19 vaccine in December with FDA approval. The company’s CEO Stéphane Bancel said if the company gets positive interim results in November from a large clinical trial. Bancel’s comments suggest Moderna’s timetable isn’t that far off from Pfizer’s, which

Moderna announces COVID-19 vaccine deal

Moderna announces COVID-19 vaccine deal

CAMBRIDGE, Mass.— Moderna announced that the U.S. government has secured 100 million doses of mRNA-1273 as part of the U.S. government’s goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of mRNA-1273

AWS powers Moderna’s digital biotechnology platform

AWS powers Moderna’s digital biotechnology platform

SEATTLE — Amazon Web Services (AWS), an Amazon.com company, announced Wednesday that Moderna  has selected AWS as its preferred cloud provider, as well as its standard for analytics and machine learning workloads. Leveraging its mRNA platform and manufacturing facility with the AWS-powered research engine, Moderna delivered the first clinical batch of its vaccine candidate (mRNA-1273)

Moderna’s COVID-19 vaccine moving to a bigger study

Moderna’s COVID-19 vaccine moving to a bigger study

NEW YORK — According to a story in the Wall Street Journal, details about the first human study of Moderna Inc.’s experimental coronavirus vaccine emerged Tuesday, which researchers said reinforced their decision to take the shot into a large, decisive clinical trial scheduled to start in late July. The new results, published online by the New